Our High-Quality Genomic Testing Portfolio

IDENTIFYING POTENTIAL TREATMENT OPTIONS AND SUPPORTING RESEARCHERS

We are the only company to offer both tissue and blood-based comprehensive genomic profiling tests that are approved by the U.S. Food and Drug Administration. Our tests help physicians create personalized treatment plans and support researchers in uncovering new biomarkers.

<table>
<thead>
<tr>
<th>Product</th>
<th>Cancer Type</th>
<th>Biopsy Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>FoundationOne®CDx</td>
<td>All Solid Tumors</td>
<td>Tissue-based Biopsy</td>
</tr>
<tr>
<td>FoundationOne®Liquid CDx</td>
<td>All Solid Tumors</td>
<td>Blood-based Biopsy</td>
</tr>
<tr>
<td>FoundationOne®Heme</td>
<td>Hematologic Malignancies &amp; Sarcomas</td>
<td>Tissue-based Biopsy or Blood-based Biopsy</td>
</tr>
<tr>
<td>FoundationOne®RNA</td>
<td>All Solid Tumors</td>
<td>Tissue-based Biopsy</td>
</tr>
</tbody>
</table>

(Monitoring Type)

Our circulating tumor DNA (ctDNA) monitoring tests may help physicians and researchers identify patients who are resistant to their current treatment and may need a different therapy, or those who are responding well and need tailoring to their treatment plan.

<table>
<thead>
<tr>
<th>Product</th>
<th>Cancer Type</th>
<th>Monitoring Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>FoundationOne®Tracker</td>
<td>All Solid Tumors</td>
<td>Tissue-informed, uses a tissue baseline derived from FoundationOne®CDx followed by a simple blood draw at each timepoint to monitor changes to ctDNA levels</td>
</tr>
<tr>
<td>FoundationOne®Monitor</td>
<td>All Solid Tumors</td>
<td>Tissue-naive, tests blood only to monitor changes to ctDNA levels</td>
</tr>
</tbody>
</table>
Global Leader in Companion Diagnostics Approvals

Foundation Medicine is a leading companion diagnostics developer with nearly 60% of all approved companion diagnostic (CDx) indications for next generation sequencing testing across the United States and Japan2,3.

Companion diagnostics are high-quality tests proven to accurately match a patient to a targeted therapy or immunotherapy1. They are approved by the U.S. Food and Drug Administration (FDA) based on clinical trials designed to demonstrate the patients who may or may not benefit from a particular drug.

Powering Scientific Breakthroughs

We are committed to pushing the boundaries of science with the goal of delivering breakthroughs that help more patients in the future. We drive complex biomarker research and discovery that guide the development of more precise treatment options. We partner with biopharmaceutical organizations globally to accelerate the development of new therapies by designing more efficient clinical trials and developing companion diagnostics. We are working to demonstrate utility of our testing in earlier stages of disease and to advance our monitoring technology to detect a patient’s response to therapy through a simple blood draw.

Our Research Impact

- 850+ clinical trials supported since 2012
- 800+ total peer reviewed publications since 2011
- 600K+ de-identified patient tumor samples available for research use via our FoundationCore database
- In 2022, collaborated with 250+ cancer centers and research institutions to advance cancer research through clinical trials and publications
- 125K+ linked patient profiles available in the Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB) enabling analysis of how genomic information impacts patient outcomes

Social and Environmental Responsibility Initiatives

Foundation Medicine is committed to reducing our overall environmental impact and investing in programs that bring equity and inclusivity to our patients and employees.

- Registered all new buildings with the LEED® green building program and are committed to responsible sourcing of utilities and minimizing our waste stream.
- Issued “Call for Grants Notification” and awarded $100,000 to catalyze programs focused on closing existing disparities in care by increasing genomic testing education, awareness and access among underserved populations in the United States5.

Corporate Awards & Recognition

USA

- Boston Business Journal Best Place to Work 2022, 2023
- Newsweek, America’s 100 Most Loved Workplaces 2023
- San Diego Business Journal Best Place to Work 2022, 2023
- Triangle Business Journal Best Place to Work 2022

Germany

- kununu Top Company 2022, 2023, 2024
- Top 100 Best Workplaces in Germany 2023
- TOP 100 Innovator in Germany 2022, 2023

References

1. Data on File, Foundation Medicine, Inc., 2023. Based on US settled claims for FoundationOne®CDx, FoundationOne®Liquid CDx, FoundationOne®Herne, and PD-L1 IHC ordered from Foundation Medicine, reported between 1/1/22 and 3/31/23 before considering any financial assistance. 65% of commercially insured and 96% of Medicare and Medicare Advantage patients owe $0 for Foundation Medicine testing.

FoundationOne®CDx and FoundationOne®Liquid CDx are next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. They are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive for labeled use of any specific therapeutic product. Use does not guarantee a match to treatment or that all relevant alterations will be found. For the complete labels please visit www.FoundationOneCDx.com and www.FoundationOneLiquidCDx.com.